Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03743636 · ClinicalTrials.gov registry record · Phase 3
Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease
A Phase 3 study, sponsored by Northwestern University.
- Completed
- Registry status
- Phase 3
- Development phase
- 90
- Enrollment target
NCT03743636 is a Phase 3 study that has completed, run by Northwestern University. The registered enrollment target is 90 participants.
The verdict
NCT03743636, a Phase 3 study, has completed, sponsored by Northwestern University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 90 participants
- Enrollment target
Study Summary
NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than placebo and whether NR combined with resveratrol significantly improves walking performance more than placebo. If findings support the hypotheses, results will be used to design a large, definitive randomized clinical. The study will randomize 90 participants with PAD to one of the following three groups: NR + resveratrol, NR + placebo, or placebo + placebo.
Interventions
- OTHER Placebo
- DRUG Nicotinamide riboside
- DRUG Resveratrol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2018-10-01 |
| Est. Completion | 2023-05-23 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03743636
The ClinicalTrials.gov registry entry for NCT03743636 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Northwestern University, which has 1,209 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT03743636 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03743636 about?
NCT03743636 is a clinical study titled "Nicotinamide Riboside With and Without Resveratrol to Improve Functioning in Peripheral Artery Disease". NICE is a randomized clinical trial that will examine the effects of nicotinamide riboside (NR) both with and without resveratrol to test whether, among people with PAD, NR significantly improves walking performance more than placebo and whether NR combined with resveratrol significantly improves wa...
What is the current status of trial NCT03743636?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 90 participants. The study started on 2018-10-01. Estimated completion is 2023-05-23.
What interventions are being tested in trial NCT03743636?
The interventions under investigation include: Placebo (OTHER), Nicotinamide riboside (DRUG), Resveratrol (DRUG).
Who is sponsoring clinical trial NCT03743636?
This trial is sponsored by Northwestern University, which has 1,209 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.